Pure Global AI
NCT06391931Recruiting

A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patients Undergoing Elective Surgery

Haisco Pharmaceutical Group Co., Ltd.Phase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Anesthesia
Drug/Device/Intervention
Cipepofol
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Haisco Pharmaceutical Group Co., Ltd.
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 3
Start date
Apr 07, 2024
End date
Jan 01, 2025
Enrollment
186 participants
Primary outcome

Success rate of anesthesia

Summary

A multicenter, open, controlled, Phase III clinical study to evaluate the efficacy and safety
 of Cipepofol injection for general anesthesia in pediatric patients undergoing elective
 surgery

ICD-10 classifications
Anaesthetic, unspecifiedOther and unspecified general anaestheticsLocal anaestheticsOther complications of anaesthesiaComplication of anaesthesia during labour and delivery, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06391931
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06391931 through Pure Global AI's free database. This Phase 3 trial is sponsored by Haisco Pharmaceutical Group Co., Ltd. and is currently Recruiting. The study focuses on Anesthesia. Target enrollment is 186 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.